of sanofi-aventis). It avapro 150mg jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the avapro 150mg names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 References3 See also[edit] Clinical useMain article: Angiotensin II receptor antagonists.

(IUPAC) name2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-oneIdentifiersCAS number 138402-11-6ATC code C09CA04PubChem 3749DrugBank APRD00413Chemical dataFormula C25H28N6OMol. mass 428.53SMILES eMolecules & avapro 150mg dataBioavailability 60–80%Metabolism avapro 150mg (CYP2C9)Half life 11–15 hoursExcretion Renal 20%, faecal 65%Therapeutic considerationsLicence data EU, USPregnancy cat. D (Au)Legal status S4 (Au), POM (UK), ?-only (U.S.)Routes OralIrbesartan (INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan is indicated for the avapro 150mg of hypertension. Irbesartan was developed by Sanofi avapro 150mg (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb avapro 150mg the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 References3 See also[edit] Clinical useMain article: Angiotensin II receptor antagonists, irbesartan.

antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade.